The estimated Net Worth of Mark Lappe is at least 11 百万$ dollars as of 6 September 2024. Mr Lappe owns over 44,000 units of Inhibrx stock worth over 9,983,220$ and over the last 2 years he sold INBX stock worth over 0$. In addition, he makes 994,281$ as Founder、 Chairman、 Pres & CEO at Inhibrx.
Mr has made over 3 trades of the Inhibrx stock since 2024, according to the Form 4 filled with the SEC. Most recently he bought 44,000 units of INBX stock worth 671,000$ on 6 September 2024.
The largest trade he's ever made was buying 44,000 units of Inhibrx stock on 6 September 2024 worth over 671,000$. On average, Mr trades about 24,800 units every 3 days since 2023. As of 6 September 2024 he still owns at least 665,548 units of Inhibrx stock.
You can see the complete history of Mr Lappe stock trades at the bottom of the page.
Mark Paul Lappe is the Founder, Chairman, Pres & CEO at Inhibrx.
As the Founder、 Chairman、 Pres & CEO of Inhibrx, the total compensation of Mr Lappe at Inhibrx is 994,281$. There are no executives at Inhibrx getting paid more.
Mr Lappe is 54, he's been the Founder、 Chairman、 Pres & CEO of Inhibrx since . There are no older and 4 younger executives at Inhibrx.
Mark's mailing address filed with the SEC is C/O INHIBRX BIOSCIENCES, INC., 11025 NORTH TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037.
Over the last 4 years, insiders at Inhibrx have traded over 27,711,393$ worth of Inhibrx stock and bought 2,717,119 units worth 64,845,764$ . The most active insiders traders include Global Investors Lp Viking ...、Capital Management, L.P.Kol...、Global Investors Lp Viking .... On average, Inhibrx executives and independent directors trade stock every 42 days with the average trade being worth of 1,598,400$. The most recent stock trade was executed by Mark Lappe on 6 September 2024, trading 44,000 units of INBX stock currently worth 671,000$.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrx executives and other stock owners filed with the SEC include: